254 related articles for article (PubMed ID: 34512646)
1. The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers.
O'Brian D; Prunty M; Hill A; Shoag J
Front Immunol; 2021; 12():721989. PubMed ID: 34512646
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
[TBL] [Abstract][Full Text] [Related]
3. The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate.
Hall WA; Nickleach DC; Master VA; Prabhu RS; Rossi PJ; Godette K; Cooper S; Jani AB
Cancer; 2013 Sep; 119(18):3272-9. PubMed ID: 23818401
[TBL] [Abstract][Full Text] [Related]
4. The Microbiome and Genitourinary Cancer: A Collaborative Review.
Markowski MC; Boorjian SA; Burton JP; Hahn NM; Ingersoll MA; Maleki Vareki S; Pal SK; Sfanos KS
Eur Urol; 2019 Apr; 75(4):637-646. PubMed ID: 30655087
[TBL] [Abstract][Full Text] [Related]
5. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder.
Eggers H; Seidel C; Schrader AJ; Lehmann R; Wegener G; Kuczyk MA; Steffens S
Med Oncol; 2013 Dec; 30(4):705. PubMed ID: 24005810
[TBL] [Abstract][Full Text] [Related]
6. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.
Sinik Z; Alkibay T; Ataoglu O; Biri H; Sözen S; Deniz N; Karaoglan U; Bozkirli I
Int J Urol; 1997 Nov; 4(6):546-51. PubMed ID: 9477181
[TBL] [Abstract][Full Text] [Related]
7. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies].
Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S
Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer.
Cimadamore A; Gasparrini S; Santoni M; Cheng L; Lopez-Beltran A; Battelli N; Massari F; Giunchi F; Fiorentino M; Scarpelli M; Montironi R
Expert Rev Mol Diagn; 2018 Jul; 18(7):645-655. PubMed ID: 29912582
[TBL] [Abstract][Full Text] [Related]
9. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
10. Hydrogen Sulfide: Emerging Role in Bladder, Kidney, and Prostate Malignancies.
Akbari M; Sogutdelen E; Juriasingani S; Sener A
Oxid Med Cell Longev; 2019; 2019():2360945. PubMed ID: 31781328
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis.
Hu Q; Gou Y; Sun C; Ding W; Xu K; Gu B; Xia G; Ding Q
Urol Oncol; 2014 Jan; 32(1):50.e1-8. PubMed ID: 24239465
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update.
Cox RM; Magi-Galluzzi C; McKenney JK
Adv Anat Pathol; 2018 Nov; 25(6):387-399. PubMed ID: 30157041
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
Matulewicz RS; Basak R; Zambrano I; Dearing BA; Schatz D; El Shahawy O; Sherman S; Bjurlin MA
J Urol; 2021 May; 205(5):1444-1451. PubMed ID: 33347778
[TBL] [Abstract][Full Text] [Related]
15. Urological tumours: recent changes.
Gardiner RA
Aust N Z J Surg; 1995 May; 65(5):350-8. PubMed ID: 7537956
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of current developments in genitourinary pathology.
Zhou AG; Owens CL; Cosar EF; Jiang Z
Arch Pathol Lab Med; 2013 Jul; 137(7):887-93. PubMed ID: 23808460
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
Yoshida S; Saito K; Koga F; Yokoyama M; Kageyama Y; Masuda H; Kobayashi T; Kawakami S; Kihara K
BJU Int; 2008 Apr; 101(8):978-81. PubMed ID: 18190628
[TBL] [Abstract][Full Text] [Related]
18. The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?
Zhang N; Bian Q; Gao Y; Wang Q; Shi Y; Li X; Ma X; Chen H; Zhao Z; Yu H
Technol Cancer Res Treat; 2023; 22():15330338231175733. PubMed ID: 37246525
[TBL] [Abstract][Full Text] [Related]
19. Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.
Al Hussein Al Awamlh B; Shoag JE; Ravikumar V; Posada L; Taylor BL; van der Mijn JC; Khan AI; Fainberg J; Al Hussein Alawamlh O; Scherr DS
J Urol; 2019 Dec; 202(6):1248-1254. PubMed ID: 31290707
[TBL] [Abstract][Full Text] [Related]
20. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
